Market capitalization | $2.03b |
Enterprise Value | $1.74b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.02 |
P/S ratio (TTM) P/S ratio | 3.52 |
P/B ratio (TTM) P/B ratio | 5.63 |
Revenue growth (TTM) Revenue growth | 14.63% |
Revenue (TTM) Revenue | $577.74m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Novocure Ltd. forecast:
7 Analysts have issued a Novocure Ltd. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 578 578 |
15%
15%
|
|
Gross Profit | 442 442 |
17%
17%
|
|
EBITDA | -139 -139 |
35%
35%
|
EBIT (Operating Income) EBIT | -150 -150 |
33%
33%
|
Net Profit | -150 -150 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Head office | Jersey |
CEO | Asaf Danziger |
Employees | 1,453 |
Founded | 2000 |
Website | www.novocure.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.